CN110179976A - Combined pharmaceutical formulation for treating cancer - Google Patents
Combined pharmaceutical formulation for treating cancer Download PDFInfo
- Publication number
- CN110179976A CN110179976A CN201910427154.1A CN201910427154A CN110179976A CN 110179976 A CN110179976 A CN 110179976A CN 201910427154 A CN201910427154 A CN 201910427154A CN 110179976 A CN110179976 A CN 110179976A
- Authority
- CN
- China
- Prior art keywords
- antibody
- cancer
- pharmaceutical formulation
- pirfenidone
- combined pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 46
- 201000011510 cancer Diseases 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960003073 pirfenidone Drugs 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 17
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract 7
- 239000000203 mixture Substances 0.000 claims abstract 2
- 239000000463 material Substances 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960003194 meglumine Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 229960002737 fructose Drugs 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000002649 immunization Methods 0.000 abstract description 5
- 230000003053 immunization Effects 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 230000005909 tumor killing Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000002504 physiological saline solution Substances 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- HQWNTNFZAGSJAX-UHFFFAOYSA-N 1-phenylpyridin-2-one Chemical compound O=C1C=CC=CN1C1=CC=CC=C1 HQWNTNFZAGSJAX-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002300 anti-fibrosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- -1 sorbierite Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a kind of combined pharmaceutical formulation for treating cancer, and the composition of medicine includes a effective amount of PD-L1 antibody and pirfenidone;The effective percentage of immunization therapy can be improved in pharmaceutical preparation of the present invention, solves the problems, such as that existing PD-L1 antibody list medicine tumor killing effect is bad, and more cancer patients is allowed to be benefited.
Description
Technical field
The present invention relates to treating cancer fields, and in particular to a kind of combined pharmaceutical formulation for treating cancer.
Background technique
Apoptosis albumen -1 (programmed death-1, PD-1) and its ligand (PD-L1) inhibitor are
Immunologic test point monoclonal antibody medicine, has with the kinds cancers patients such as melanoma, non-small cell lung cancer and urothelial cancer
Good curative effect.It not only changes the treatment mode of malignant tumour, also extends total life span of patient.In tumour micro-loop
In border, PD-L1 antibody can target the combination of competition PD-L1 and PD-1, release t cell activation and inhibit, make antigen presenting cell more
Antigen presentation to T cell and is efficiently made into T cell differentiation activation.
However, effective percentage of the immunization therapy with cancer patient is only 20% or so, it is current for how improving effective percentage
Urgent problem to be solved.Have a large number of studies show that, the collagen stroma in tumor microenvironment can form fibrin barriers, prevent immune thin
The infiltration of born of the same parents makes patient generate primary or secondary resistance to immunization therapy.
Therefore, inhibit collagen to be formed, reduce fiber deposition to may be a kind of raising immunization therapy efficient way.
Summary of the invention
The present invention problem not ideal enough for existing PD-L1 antibody list medicine cancer resistant effect provides a kind of for treating
The combined pharmaceutical formulation of cancer, the pharmaceutical preparation use effective dose PD-L1 antibody (- 1 antibody of apoptosis albumen)
The remarkable effect in terms of inhibiting tumour growth is used in combination with pirfenidone, has combined immunologic test point inhibitor and anti-fiber
Chemical drug object can solve the problems, such as that some patientss react bad to immunologic test point inhibitor.
To achieve the above object, a kind of combined pharmaceutical formulation for treating cancer designed by the present invention, the combination medicine
Object includes a effective amount of PD-L1 antibody and pirfenidone.
Pirfenidone is a kind of new pyridine compounds with wide spectrum anti-fibrosis effect, entitled 5 methyl 1 of chemistry
Phenyl 2- (1 H) pyridone is a kind of white or light yellow crystalline powder, can prevent and reverse fibrosis and scar
It is formed.It was listed by the wild justice of Japanese salt in 2008, has obtained U.S. Food and Drug Administration's approval, be first and pass through weight
Multiple, random, placebo III clinical trial phase proves the drug for having certain curative effect to idiopathic pulmonary fibrosis (IPF).
Pirfenidone can inhibit fibroblast proliferation in the present invention, and fibroblast is prevented to convert to flesh at fiber,
It reduces and promotees the expression of fiber correlation factor.Therefore, being used to enhance the curative effect of immunologic test point inhibitor for pirfenidone auxiliary is one
A effective method.
Further, in the pharmaceutical preparation, the content of pirfenidone be 10-50mg/ml, PD-L1 antibody be 0.1~
0.3mg/ml。
Still further, the quality proportioning of PD-L1 antibody and pirfenidone is 1:100~300 in the pharmaceutical preparation.
Still further, the content of the pirfenidone is that 20-30mg/ml, PD-L1 antibody are in the pharmaceutical preparation
0.1mg/ml。
Still further, the content of the pirfenidone is that 30mg/ml, PD-L1 antibody are in the pharmaceutical preparation
0.1mg/ml。
Still further, the pharmaceutical preparation further includes pharmaceutically acceptable auxiliary material.
Still further, the auxiliary material is physiological saline, glucose solution, vitamin C, sorbierite, mannitol, xylose
Any one in alcohol, fructose, amino acid, meglumine, dextrin, magnesium stearate and sucrose or two kinds.
Still further, the cancer is lung cancer, colon cancer.
Beneficial effects of the present invention:
The effective percentage of immunization therapy can be improved in pharmaceutical preparation of the present invention, solves existing PD-L1 antibody list medicine suppression
The bad problem of tumor effect allows more cancer patients to be benefited.
Detailed description of the invention
Fig. 1 is mouse tumor volume growth curve figure (* indicates P < 0.05);
In figure, left figure is mice lung cancer model growth curve chart;Right figure is mouse junction cancer model growth curve chart;
Fig. 2 is mouse survival curve graph;
In figure, left figure is mice lung cancer model survivorship curve figure;Right figure is mouse junction cancer model survivorship curve figure;
Fig. 3 is with CD45+ immunocyte infiltration degree in Flow cytometry tumor tissues;
In figure, Fig. 3 a is the streaming schematic diagram that CD45+ immunocyte accounts for live cell fraction;Fig. 3 b is CD45+ immunocyte
Account for the statistical chart of live cell fraction;
Fig. 4 is with CD8+ immunocyte infiltration degree in Flow cytometry tumor tissues;
In figure, Fig. 4 a is the streaming schematic diagram of the total T cell ratio of CD8+T cell Zhan;Fig. 4 b is that the total T of CD8+T cell Zhan is thin
The statistical chart of born of the same parents' ratio;
Specific embodiment
The present invention is described in further detail combined with specific embodiments below, so as to those skilled in the art understand that.
Embodiment 1: inhibit the effect of tumour growth in pirfenidone combined PD-L1 antibody body
Test material therefor: normal 6-8 week old female C57BL/6 mouse is several, the strain of MC38 mouse colonic cell, LLC are small
Mouse lung cancer cell line, pirfenidone, PD-L1 antibody, 1640 culture mediums, 10% fetal calf serum, sterile PBS;
Mouse experiment process is as follows:
1) the right back hair of mouse is shaved with shave, 1*10 is subcutaneously injected6A MC38 tumour cell;
2) region tumors volume 100cm to be seeded3When, mouse is randomly divided into 4 groups, control group (control, abdominal cavity note
Penetrate sterile PBS), pirfenidone list medicine group (PFD, be injected intraperitoneally pirfenidone 300mg/kg), PD-L1 antibody list medicine group (α PD-
L1, be injected intraperitoneally PD-L1 antibody 2mg/kg), joint group (PFD+ α PD-L1, be injected intraperitoneally hybrid medicine, contain pirfenidone
300mg/kg, PD-L1 antibody 2mg/kg).It is administered once a day, until mouse leads to death or tumour because tumor load is overweight
Volume is more than 2000cm3;
3) a mouse tumor volume is measured every three days, when gross tumor volume is more than 2000cm3When, put to death mouse.
Experimental result:
1, PD-L1 antibody list medicine group Tumor growth inhibition acts on unobvious (Fig. 1);
2, pirfenidone list medicine can inhibit tumour growth, but mouse has no that obvious existence benefits (Fig. 1~2);
3, two medicine joint group mice tumors grews inhibit obvious, and more single medicine group effect is good, reaches statistical significance;Joint group
The mouse survival time is obviously prolonged (Fig. 1~2).
Embodiment 2: the influence of pirfenidone combined PD-L1 Antibody on Mouse tumor microenvironment
Test material therefor: normal 6-8 week old female C57BL/6 mouse is several, MC38 cell strain, pirfenidone, PD-L1 are anti-
Body, 1640 culture mediums, 10% fetal calf serum, sterile PBS, IV Collagenase Type, fluorescent marker antibody (Cy5.5 anti-mouse
CD4, APC anti-mouse CD8, FITC anti-mouse CD45), BD LSRII streaming instrument;
Experiment flow:
1) it is inoculated with oncocyte, dosing step is same as Example 1;
2) it is administered the tenth day, puts to death mouse, go out subcutaneous tumors, knurl is subtracted into fritter, be digested to list with IV Collagenase Type
Cell suspension;
3) single cell suspension is divided into several tubules, be centrifuged, abandon supernatant, the antibody mixing of fluorescent marker is added into precipitating
Liquid, 4 degree are incubated for 30 minutes;
4) antibody is washed away with PBS, cell is resuspended with 500 microlitres of PBS, is detected with flow cytometer, it is soft with Flowjo
Part analyzes result.
Experimental result:
1, Fig. 3 A is shown, two medicine joint groups compare control, single medicine group, immunocyte (CD45+ leucocyte) increasing proportion;Figure
3B shows immunocyte increasing proportion in joint group per unit weight tumour;-
2, Fig. 4 A is shown, two medicine joint groups compare control group, single medicine group, cytotoxic T cell (CD8+ lymphocyte) ratio
Example increases;Fig. 4 B shows T cell increasing proportion in joint group per unit weight tumour;
Therefore, the immune microenvironment of tumour can be changed in drug combination, enhances the anti-tumor effect of body itself, to reach
Inhibit the effect of tumour growth.
Embodiment 3
Combined pharmaceutical formulation 1 for treating cancer, wherein the content of pirfenidone is that 10mg/ml, PD-L1 antibody are
0.3mg/ml, remaining is physiological saline.
Embodiment 4
Combined pharmaceutical formulation 2 for treating cancer, wherein the content of pirfenidone is that 30mg/ml, PD-L1 antibody are
0.1mg/ml, remaining is physiological saline.
Embodiment 5
Combined pharmaceutical formulation 3 for treating cancer, wherein the content of pirfenidone is that 10mg/ml, PD-L1 antibody are
0.1mg/ml, remaining is physiological saline.
Embodiment 6
Combined pharmaceutical formulation 4 for treating cancer, wherein in the pharmaceutical preparation, the content of pirfenidone is 20mg/
Ml, PD-L1 antibody are 0.1mg/ml, remaining is physiological saline.
Embodiment 7
Combined pharmaceutical formulation 5 for treating cancer, wherein in the pharmaceutical preparation, the content of pirfenidone is 50mg/
Ml, PD-L1 antibody are 0.1mg/ml, remaining is physiological saline.
Embodiment 8
Combined pharmaceutical formulation 6 for treating cancer, wherein in the pharmaceutical preparation, the content of pirfenidone is 30mg/
Ml, PD-L1 antibody are 0.1mg/ml, remaining is physiological saline.
Other unspecified parts are the prior art.Although above-described embodiment is made that the present invention and retouches in detail
State, but it is only a part of the embodiment of the present invention, rather than whole embodiments, people can also according to the present embodiment without
Other embodiments are obtained under the premise of creativeness, these embodiments belong to the scope of the present invention.
Claims (8)
1. a kind of combined pharmaceutical formulation for treating cancer, it is characterised in that: the composition of medicine includes a effective amount of PD-L1
Antibody and pirfenidone.
2. being used for the combined pharmaceutical formulation of anticancer according to claim 1, it is characterised in that: in the pharmaceutical preparation, pyrrole is non-
The content of Buddhist nun's ketone is that 10-50mg/ml, PD-L1 antibody are 0.1~0.3mg/ml.
3. being used for the combined pharmaceutical formulation for the treatment of cancer according to claim 2, it is characterised in that: in the pharmaceutical preparation,
The quality proportioning of PD-L1 antibody and pirfenidone is 1:100~300.
4. being used for the combined pharmaceutical formulation for the treatment of cancer according to claim 3, it is characterised in that: in the pharmaceutical preparation,
The content of pirfenidone is that 20-30mg/ml, PD-L1 antibody are 0.1mg/ml.
5. being used for the combined pharmaceutical formulation for the treatment of cancer according to claim 5, it is characterised in that: in the pharmaceutical preparation,
In the pharmaceutical preparation, the content of the pirfenidone is that 30mg/ml, PD-L1 antibody are 0.1mg/ml.
6. being used for the combined pharmaceutical formulation for the treatment of cancer described according to claim 1~any one of 5, it is characterised in that: institute
Stating pharmaceutical preparation further includes pharmaceutically acceptable auxiliary material.
7. being used for the combined pharmaceutical formulation for the treatment of cancer according to claim 6, it is characterised in that: the auxiliary material is physiology salt
Water, glucose solution, vitamin C, sorbierite, mannitol, xylitol, fructose, amino acid, meglumine, dextrin, magnesium stearate and
Any one in sucrose or two kinds.
8. according to claim 1 be used for treating cancer combined pharmaceutical formulation, it is characterised in that: the cancer be lung cancer or
Colon cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910427154.1A CN110179976A (en) | 2019-05-22 | 2019-05-22 | Combined pharmaceutical formulation for treating cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910427154.1A CN110179976A (en) | 2019-05-22 | 2019-05-22 | Combined pharmaceutical formulation for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110179976A true CN110179976A (en) | 2019-08-30 |
Family
ID=67717225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910427154.1A Pending CN110179976A (en) | 2019-05-22 | 2019-05-22 | Combined pharmaceutical formulation for treating cancer |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110179976A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022538A (en) * | 1995-06-06 | 2000-02-08 | The Wistar Institute Of Anatomy And Biology | Method of treating malignancies |
CN109312408A (en) * | 2016-05-17 | 2019-02-05 | 豪夫迈·罗氏有限公司 | For diagnosing and signing for matrix gene used in immunotherapy |
-
2019
- 2019-05-22 CN CN201910427154.1A patent/CN110179976A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6022538A (en) * | 1995-06-06 | 2000-02-08 | The Wistar Institute Of Anatomy And Biology | Method of treating malignancies |
CN109312408A (en) * | 2016-05-17 | 2019-02-05 | 豪夫迈·罗氏有限公司 | For diagnosing and signing for matrix gene used in immunotherapy |
Non-Patent Citations (1)
Title |
---|
王海洋、俞晓晴: "免疫检查点抑制剂一线治疗晚期NSCLC的", 《中国肺癌杂志》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111065411B (en) | Use of PD-1 antibody and VEGFR inhibitor for combined treatment of small cell lung cancer | |
CN101014365B (en) | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody | |
KR102002653B1 (en) | Composition comprising aflibercept, folinic acid, 5-fluorouracil(5-fu) and irinotecan(folfiri) | |
KR100861466B1 (en) | Combination therapy using anti-angiogenic agents and tnf? | |
EP0806963B1 (en) | Carcinoma treatment | |
CN108136025A (en) | A kind of novel method using immune modulating treatment cancer | |
KR20170015460A (en) | Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy | |
CN108136022A (en) | Use B-RAF inhibitor and the method for immunologic test point inhibitor for treating cancer | |
AU2002316855A1 (en) | Combination therapy using anti-angiogenic agents and TNFalpha | |
CN110494152A (en) | Short TRAIL antibody and application method | |
CN114870009A (en) | Anti-tumor combined composition, application thereof and anti-tumor medicine | |
CN101920015A (en) | Pharmaceutical composition for cancer treatment | |
CN111920948B (en) | Pharmaceutical composition comprising immune cells for treating cancer | |
KR20190091299A (en) | Pharmaceutical compositions for use in the treatment of cancer | |
CN110179976A (en) | Combined pharmaceutical formulation for treating cancer | |
TW202114647A (en) | Small molecule inhibitor for treating cancer in tumor subject with high interstitial fluid pressure | |
US20230270861A1 (en) | Inhibitors of the Artemin Pathway for Treatment of Cancer | |
CN111419832B (en) | Pharmaceutical composition and application thereof in preparation of tumor treatment drugs | |
AU2020338366B2 (en) | Phenothiazines and their derivatives for use as a medicament | |
CN112194723B (en) | Application of immune cells in treating cancer | |
AU2020101967A4 (en) | Combined pharmaceutical preparation for treating cancer | |
WO2021182572A1 (en) | Medicament for treatment and/or prevention of cancer | |
Saurez-Martínez et al. | Nimotuzumab, inmunoterapia eficaz para el tratamiento de tumores epiteliales malignos | |
Zhou et al. | Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis | |
CN117224689B (en) | Use of a combination of an anti-HER 2 antibody and a chemotherapeutic agent for the treatment of gastric cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190830 |